-
Saisin Pharma completes $100 million round A financing to focus on the development of new drugs for the central nervous system
Time of Update: 2021-01-16
On December 8th SciNeuro Pharmaceuticals announced the official launch and completion of a $100m round of A financing, focusing on the development of innovative drugs for patients with central nervous system (CNS) diseases.
-
Asasin Pharma has released positive data for the new drug Oribatinib Critical Registration Phase II study
Time of Update: 2021-01-03
HQP1351 is a new class 1 drug developed by AXA Pharmaceuticals and is a new third-generation BCR-ABL tyrosine kinase inhibitor (TYrosine Kinase Inhibitor, TKI) for the treatment of chronic myeloid leukemia (CML) resistant to first- and second
-
BioNTech and Fosun Pharma have announced an agreement to supply mRNA with a new coronary nucleic acid vaccine in China
Time of Update: 2020-12-26
., Ltd. ("Fosun Pharma" or "Group", stock code: 600196. SH, 02196.HK) announced that the two sides have reached an agreement on the supply and production of the new mRNA coronary nucleic acid vaccine in Chinese mainland, and bioNTech expects to supply
-
Saisin Pharma completes $100 million round A financing to focus on the development of new drugs for the central nervous system
Time of Update: 2020-12-24
addition, the core team of Saisan Pharma includes Dr. Qiuqing Ang, Chief Medical Officer, Dr. Danny Chen, Senior Vice President and Head of Translational Sciences, and Dr. Paul Stead, Chief Commercial Officer.
-
Dialogue Fosun Pharma Back to Emin: The latest developments in the mRNA new crown vaccine BNT162b2
Time of Update: 2020-12-20
the advantages of this vaccine? Dr. Hui: We've been looking at mRNA for almost three years, and I'm personally very bullish on mRNA because of its wide application. protein is a biological unit of function, a variety of human functions, are carried out
-
Fosun Pharma's First-in-class new drug has been approved clinically by the FDA
Time of Update: 2020-11-07
ORIN1001 is an original (First-in-Class) small molecule drug with new enzyme-type targets, new mechanism of action and new chemical structure type developed by Fosun Pharma for the treatment of advanced solid tumors and idiotic pulmonary fibrosis.
-
Fosun Pharma's First-in-class new drug has been approved clinically by the FDA
Time of Update: 2020-10-31
ORIN1001 is an original (First-in-Class) small molecule drug with new enzyme-type targets, new mechanism of action and new chemical structure type developed for Fosun Pharma, which is intended for the treatment of advanced solid tumors and idioblastical pulmonary fibrosis.
-
Research and development daily Fosun Pharma First-in-class new drug approved clinically by the FDA.
Time of Update: 2020-10-30
, targeting CD19 and BCMA. Yiming Anko VEGF/PD-L1 dual specific antibody clinical application was accepted by CDE 21, CDE latest publicity, Yiming Anke Class 1 bio-new drug injection IM2510 clinical application was accepted. is a dual-specific
-
Fosun Pharma's new adaptation to Avalanco Pak has been approved for the near future start-up of Phase III clinical practice.
Time of Update: 2020-10-23
On October 13, Fosun Pharma announced that its new drug, Malay acid avalanthepa tablets, had been approved by NMPA for clinical trials for chronic immunocompetitive plateroid reduction in adults (ITP).
-
Fosun Pharma and Jacobson have reached an agreement on the supply and distribution of the new crown vaccine for mRNA.
Time of Update: 2020-10-15
The main contents of the letter of intent 1, Fosun Industrial, Jacobson on the mRNA new crown vaccine in the cooperative area of the supply and distribution of cooperation reached an intention.
-
Fosun Pharma and BioNTech have announced their intention to supply 10 million doses of mRNA new crown vaccine to Hong Kong and Macao.
Time of Update: 2020-09-28
, to improve the access of vaccine products, to contribute to the global fight against the new crown epidemic. "Fosun Industrial (Hong Kong) Co., Ltd., a wholly owned subsidiary of Fosun Pharmaceuticals, signed a letter of intent for the vaccine
-
New drug for Parkinson's disease! The third generation of powerful COMT inhibitor Ongentys
Time of Update: 2020-09-27
or levodopa-benserazide hydrochloride for adult patients with Parkinson's disease (PD), end-of-dose movement fluctuations (effect reduction, wearing-off phenomenon). Ongentys' active drug ingredient, opicapone, was developed by the Portuguese
-
New drug for Parkinson's disease! The third generation of powerful COMT inhibitor Ongentys
Time of Update: 2020-09-26
was approved in the European Union as an ad-side therapy for DDCi,DDCi, such as carbidobas, in adult PD patients who received these combination therapies that could not stabilize end-of-dose movement fluctuations (reduced efficacy, wearing-off
-
Shanghai Pharma has been granted the exclusive rights of the new generation of lysovirus therapy for Yino Micropharmaceuticals in Greater China.
Time of Update: 2020-09-16
based on the annual net sales of the MVR-T3011. , was founded in 2015, the company's chairman and chief executive officer is Zhou Guoxuan academician. company is committed to the development of a new generation of lysolytic tumor virus, while
-
A new milestone in ten months! Asaan Pharma was included in the Hang Seng Composite Index and other three major indices.
Time of Update: 2020-09-08
and performance measures using the weighted method of market capitalization in circulation, with 485 shares now in the stock market. the index covers the highest total market capitalisation of securities listed on the Main Board of the Hong
-
Fosun Pharma's new crown mRNA vaccine has been activated clinically 72 subjects have been vaccinated.
Time of Update: 2020-08-14
The Clinical Phase I pilot program in China recruited 144 healthy subjects to assess the safety and immunogenicity of the candidate vaccine and determine dose selection. in the first phase of clinical studies, the first group of subjects
-
Fosun Pharma's new coronavirus mRNA vaccine was registered for clinical trial review.
Time of Update: 2020-07-31
mainland and Hong Kong, Macao and Taiwan, the same below), for the vaccine for new coronaviruses. the vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronaviruses in people aged 18 and over
-
Fosun Pharma's new coronavirus mRNA vaccine Phase I clinical trial has been approved.
Time of Update: 2020-07-31
the vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronavirus pneumonia in people aged 18 and over.
-
Fosun Pharma's new coronavirus mRNA vaccine Phase I clinical trial has been approved.
Time of Update: 2020-07-31
According to the announcement, Fosun Pharmaceutical Industry in March 2020 was authorized by BioNTech SE ("BioNTech" in Germany) to develop and commercialize vaccine products based on its proprietary mRNA technology platform in the region (i.e
-
New drugs for Parkinson's disease! The third-generation powerful COMT inhibitor Ongentys (opicapone
Time of Update: 2020-07-18
, June 30, 2020 /
BIOON/ ONO PHARMACEUTICAL, JAPAN'S MINISTRY OF HEALTH AND LABOUR (MHLW), HAS APPROVED ONGENTYS (OPICAPONE) 25MG TABLET, A NEW, DAILY, ORAL SELECTIVE PEDIATRIC TEA PHENOL-OXYGEN-METHYL TRANSFERASE (MHLWYNE) COMT
